Literature DB >> 28986630

Comparison of transient severe motion in gadoxetate disodium and gadopentetate dimeglumine-enhanced MRI: effect of modified breath-holding method.

Ji Soo Song1,2,3, Eun Jung Choi4,5,6, Eun Hae Park4,5,6, Ju-Hyung Lee7.   

Abstract

OBJECTIVES: To compare the occurrence of transient severe motion (TSM) between gadoxetate disodium- and gadopentetate dimeglumine-enhanced MRI and between gadoxetate disodium-enhanced MRI scans obtained with and without the application of a modified breath-holding technique.
METHODS: We reviewed 80 patients who underwent two magnetic resonance examinations (gadoxetate disodium-enhanced MRI and gadopentetate dimeglumine-enhanced MRI) with the application of a modified breath-holding technique (dual group). This group was compared with 100 patients who underwent gadoxetate disodium-enhanced MRI without the application of the modified breath-holding technique (single group). Patient risk factors and motion scores (1 [none] to 5 [non-diagnostic]) for each dynamic-phase imaging were analysed.
RESULTS: In the dual group, mean motion scores did not differ significantly between gadoxetate disodium- and gadopentetate dimeglumine-enhanced MRI (p=0.096-0.807) in any phase. However, in all phases except the late dynamic phase, mean motion scores of the dual group were significantly lower than those in the single group. TSM incidence did not differ significantly between gadoxetate disodium- and gadopentetate dimeglumine-enhanced MRI in the dual group (3.8% vs. 1.3%, p=0.620).
CONCLUSION: With proper application of the modified breath-holding technique, TSM occurrence with gadoxetate disodium-enhanced MRI was comparable to that associated with gadopentetate dimeglumine-enhanced MRI. KEY POINTS: • The modified breath-holding method significantly reduced the incidence of TSM. • Gadoxetate disodium and gadopentetate dimeglumine showed comparable motion scores. • TSM incidence was comparable between gadoxetate disodium- and gadopentetate dimeglumine-enhanced MRI.

Entities:  

Keywords:  Arterial phase; Gadopentetate dimeglumine; Gadoxetate disodium; Magnetic resonance imaging; Motion artefact

Mesh:

Substances:

Year:  2017        PMID: 28986630     DOI: 10.1007/s00330-017-5070-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

1.  Diaphragmatic and cardiac motion during suspended breathing: preliminary experience and implications for breath-hold MR imaging.

Authors:  A E Holland; J W Goldfarb; R R Edelman
Journal:  Radiology       Date:  1998-11       Impact factor: 11.105

2.  An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging.

Authors:  Utaroh Motosugi; Peter Bannas; Candice A Bookwalter; Katsuhiro Sano; Scott B Reeder
Journal:  Radiology       Date:  2015-10-16       Impact factor: 11.105

3.  Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition.

Authors:  Jason A Pietryga; Lauren M B Burke; Daniele Marin; Tracy A Jaffe; Mustafa R Bashir
Journal:  Radiology       Date:  2014-01-21       Impact factor: 11.105

4.  Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.

Authors:  Yen-Tsung Huang; Chin-Lan Jen; Hwai-I Yang; Mei-Hsuan Lee; Jun Su; Sheng-Nan Lu; Uchenna H Iloeje; Chien-Jen Chen
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

5.  Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?

Authors:  Mustafa R Bashir; Rajan T Gupta; Matthew S Davenport; Brian C Allen; Tracy A Jaffe; Lisa M Ho; Daniel T Boll; Elmar M Merkle
Journal:  J Magn Reson Imaging       Date:  2012-09-25       Impact factor: 4.813

6.  Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences.

Authors:  Alison A Evans; Gang Chen; Eric A Ross; Fu-Min Shen; Wen-Yao Lin; W Thomas London
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-04       Impact factor: 4.254

7.  Transient severe motion in the arterial phase during gadoxetate disodium-enhanced MR imaging: evaluation of patients with multiple MR examinations.

Authors:  Won Hyeong Im; Ji Soo Song; Eun Hae Park; Hyo Sung Kwak
Journal:  Abdom Radiol (NY)       Date:  2017-10

8.  Reduction in respiratory motion artefacts on gadoxetate-enhanced MRI after training technicians to apply a simple and more patient-adapted breathing command.

Authors:  Andreas Gutzeit; Simon Matoori; Johannes M Froehlich; Constantin von Weymarn; Carolin Reischauer; Orpheus Kolokythas; Matthias Goyen; Klaus Hergan; Matthias Meissnitzer; Rosemarie Forstner; Jan D Soyka; Aleksis Doert; Dow-Mu Koh
Journal:  Eur Radiol       Date:  2015-11-16       Impact factor: 5.315

9.  Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact.

Authors:  Matthew S Davenport; Mustafa R Bashir; Jason A Pietryga; Joseph T Weber; Shokoufeh Khalatbari; Hero K Hussain
Journal:  AJR Am J Roentgenol       Date:  2014-07-23       Impact factor: 3.959

Review 10.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-10       Impact factor: 11.105

View more
  6 in total

1.  Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice.

Authors:  Marie-Luise Kromrey; Masatoshi Hori; Satoshi Goshima; Kazuto Kozaka; Tomoko Hyodo; Yuko Nakamura; Akihiro Nishie; Tsutomu Tamada; Tatsuya Shimizu; Akihiko Kanki; Utaroh Motosugi
Journal:  Eur Radiol       Date:  2019-07-23       Impact factor: 5.315

Review 2.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

3.  Reduction of respiratory motion artifacts in gadoxetate-enhanced MR with a deep learning-based filter using convolutional neural network.

Authors:  M-L Kromrey; D Tamada; H Johno; S Funayama; N Nagata; S Ichikawa; J-P Kühn; H Onishi; U Motosugi
Journal:  Eur Radiol       Date:  2020-06-17       Impact factor: 5.315

4.  A low albumin level as a risk factor for transient severe motion artifact induced by gadoxetate disodium administration: A retrospective observational study with free-breathing dynamic MRI and an experimental study in rats.

Authors:  Takumi Sugiura; Kenichiro Okumura; Motomitsu Sasaki; Junichi Matsumoto; Takahiro Ogi; Norihide Yoneda; Azusa Kitao; Kazuto Kozaka; Wataru Koda; Satoshi Kobayashi; Toshifumi Gabata
Journal:  PLoS One       Date:  2022-03-18       Impact factor: 3.240

5.  Respiratory motion artefacts in Gd-EOB-DTPA (Primovist/Eovist) and Gd-DOTA (Dotarem)-enhanced dynamic phase liver MRI after intensified and standard pre-scan patient preparation: A bi-institutional analysis.

Authors:  Christian Wybranski; Florian Siedek; Robert Damm; Angelos Gazis; Ortrud Wenzel; Stefan Haneder; Thorsten Persigehl; Susanne Steinhauser; Maciej Pech; Frank Fischbach; Katharina Fischbach
Journal:  PLoS One       Date:  2020-03-20       Impact factor: 3.240

6.  Respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine: compressed sensing MRI revealing physiologic phenomena during the entire injection cycle.

Authors:  Carl Guillaume Glessgen; Hanns-Christian Breit; Tobias Kai Block; Elmar Max Merkle; Tobias Heye; Daniel Tobias Boll
Journal:  Eur Radiol       Date:  2021-07-29       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.